AMG 102

AMG-102

On May 15, 2008, Amgen Inc. released initial results in the Phase II trial of its experimental drug AMG 102. The trial found the drug may only be effective in a subpopulation of patients who have recurring brain cancer. AMG 102 is meant to target a specific growth factor that may play a significant role in many different forms of cancer.